Quarterly ResultMay 15, 2026, 08:06 AM
GT Biopharma Q1 Net Loss $(3.37)M; Cash $8.92M; Going Concern Doubt
AI Summary
GT Biopharma reported a net loss attributable to common stockholders of $(3.37) million for Q1 2026, a significant increase from $(0.78) million in Q1 2025. Despite the higher net loss, basic and diluted net loss per share improved to $(0.11) from $(0.33) due to a substantial increase in weighted average common shares outstanding. The company's cash and cash equivalents increased to $8.92 million, but management continues to express substantial doubt about its ability to continue as a going concern. Legal proceedings, including the Ohri Matter and Z-One, LLC appeal, are ongoing.
Key Highlights
- Net loss attributable to common stockholders was $(3.37) million for Q1 2026, up from $(0.78) million in Q1 2025.
- Basic and diluted net loss per share improved to $(0.11) for Q1 2026 from $(0.33) in Q1 2025.
- Cash and cash equivalents increased to $8.92 million as of March 31, 2026, from $6.81 million at year-end 2025.
- Net cash used in operating activities was $(2.47) million for Q1 2026, compared to $(2.20) million in Q1 2025.
- Net cash provided by financing activities was $4.58 million for Q1 2026, up from $0.62 million in Q1 2025.
- Research and development expenses decreased to $0.41 million in Q1 2026 from $1.10 million in Q1 2025.
- Selling, general and administrative expenses increased to $2.44 million in Q1 2026 from $0.83 million in Q1 2025.
- Company continues to raise substantial doubt about its ability to continue as a going concern.
Price Impact
More from GTBP